Cell Gene Therapy Manufacturing Services Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The cell and gene therapy manufacturing services market encompasses contract manufacturing organizations (CMOs), contract development and manufacturing organizations (CDMOs), and ancillary service providers that support developers of cell-based and gene-based therapies. The market is valued at roughly $12.0 billion in 2025 and is forecast to grow at approximately 21.2% annually, reflecting strong underlying demand from both clinical-stage and commercial-stage therapy developers. Public estimates of the market's size vary widely depending on scope, with broader manufacturing figures ranging from about $7 billion to more than $21 billion in 2025.

• •Market value in 2025 is approximately $12.0 billion with a projected CAGR near 21.2%.
• •Service scope spans process development, GMP manufacturing, fill-finish, viral vector production, and analytical testing.
• •Estimates across public sources span roughly $7 billion to over $21 billion depending on segment definitions.

Rising clinical and commercial activity in cell and gene therapies is the primary engine of demand, with an expanding pipeline of autologous and allogeneic candidates requiring specialized production capacity. Small and mid-sized biotech sponsors, which often lack in-house manufacturing infrastructure, are increasingly outsourcing to service providers, while regulatory complexity and the technical difficulty of producing viral vectors and cell products at scale further reinforce reliance on external partners.

• •Surge in clinical-stage cell and gene therapy trials and recent commercial approvals.
• •Outsourcing by small and mid-sized biotechs that lack in-house GMP capacity.
• •High capital and technical barriers to building proprietary viral vector and cell processing facilities.

By scale, commercial-scale manufacturing commands a leading share of the market, while pre-commercial, R&D, and clinical-stage manufacturing represent the fastest-growing sub-segments as more candidates advance through trials. By service type, contract manufacturing is the largest category, followed by process development, fill-finish, and quality/analytical services. North America holds the dominant share of global revenue due to its concentration of therapy developers, established CDMOs, and supportive regulatory environment, with Europe as the second-largest region and Asia-Pacific exhibiting the fastest growth on the back of expanding biopharma ecosystems in China, Japan, South Korea, and India.

• •Commercial-scale manufacturing leads by revenue; clinical/R&D scale is the fastest-growing segment.
• •Contract manufacturing is the largest service category, followed by development and analytical services.
• •North America dominates revenue; Asia-Pacific is the fastest-growing regional market.

What are the recent trends and outlook?

Automation, closed-system processing, and digital quality analytics are reshaping manufacturing economics, with new platforms aimed at reducing cost-of-goods and scaling autologous therapies. Allogeneic, off-the-shelf cell therapies and broader use of induced pluripotent stem cells (iPSCs) are expected to shift demand toward larger-batch, lower-cost production models. Through 2035, the market is widely projected to grow at a double-digit pace, driven by continued regulatory approvals, geographic expansion of manufacturing footprints, and deeper outsourcing penetration among therapy developers.

• •Adoption of automated, closed, and digitally monitored manufacturing platforms is accelerating.
• •Allogeneic and iPSC-based therapies are reshaping production economics toward scale and standardization.
• •Long-term outlook points to sustained double-digit annual growth through the mid-2030s.